Breaking News
March 20, 2019 - FDA Approves Zulresso (brexanolone) for the Treatment of Post-Partum Depression
March 19, 2019 - How it manipulates us to tribalism
March 19, 2019 - How can doctors encourage patients to adopt healthier behaviors?
March 19, 2019 - Meet Hal: He's One Sick Robot
March 19, 2019 - Blood test and mathematical model can estimate preterm birth rate in low-resource countries
March 19, 2019 - TAVR procedure safe in patients with unusual valve anatomy
March 19, 2019 - Proteins in the eye may be potential source for cost-effective test to predict Alzheimer’s disease
March 19, 2019 - Opioid Prescriptions Dropped for New Users From 2012 to 2017
March 19, 2019 - New method may better predict the best treatment for burn wounds
March 19, 2019 - “Asian” isn’t specific enough for health data, research suggests
March 19, 2019 - ColumbiaDoctors Presents Honors for Outstanding Commitment to Patient Safety
March 19, 2019 - Innovative model identifies primate species with potential to transmit Zika in the Americas
March 19, 2019 - One-off surgery could offer hope to patients with high blood pressure
March 19, 2019 - How to Protect Your Kids From Drowning
March 19, 2019 - CEA Test: MedlinePlus Lab Test Information
March 19, 2019 - Two years after face transplant, Andy Sandness’ smile shows his progress
March 19, 2019 - Registration now open for Stanford’s Big Data in Precision Health conference
March 19, 2019 - Gene Keeps Fear at Bay, But Only in Females
March 19, 2019 - GARDP and Evotec partner to tackle growing threat of antimicrobial resistance
March 19, 2019 - Ultrasound offers precise, minimally invasive way to measure cardiac output in children
March 19, 2019 - Study suggests potential new approach to treat atopic dermatitis
March 19, 2019 - Sense of control over life makes older adults feel younger
March 19, 2019 - Study shows how probiotics influence gut microbiota
March 19, 2019 - Study offers new evidence that narcolepsy is an autoimmune condition
March 19, 2019 - Breastfeeding may offer long-term heart health benefits for women
March 19, 2019 - Study of young athletes suggests snoring and sleep apnea are linked to sudden cardiac death
March 19, 2019 - Did Your Doctor ‘Ghost’ You? An Employment Contract May Be To Blame
March 19, 2019 - Food pantry clients more likely to make healthy choices when meal kits and recipe tastings are available
March 19, 2019 - Mental health problems among children increasing
March 19, 2019 - New ISO standard helps evaluate and manage impact of environmental damage
March 19, 2019 - CardioMEMS heart failure sensor reliably safe, effectively reduces hospitalizations
March 19, 2019 - Researchers report promising results of potential reversal agent
March 19, 2019 - Scientists identify brain circuit responsible for cocaine-seeking behavior during relapse
March 19, 2019 - First African-American Neuroscience Research Initiative launched to close the gap in health disparities
March 19, 2019 - Bimekizumab Demonstrated Long-Term Maintenance of Complete or Almost Complete Skin Disease Resolution for Psoriasis Patients in BE ABLE 2 Extension Study
March 19, 2019 - Attitudes about health affect how older adults engage with negative health news
March 19, 2019 - Huron Digital Pathology to unveil new ‘Scan Index Search’ platform at USCAP 2019
March 19, 2019 - Frequent intake of sugary drinks tied to greater risk of premature death
March 19, 2019 - Bruker showcases new analytical systems and applied market solutions at Pittcon 2019
March 19, 2019 - Framingham cardiovascular risk prediction model from the 1990s still gives the best results
March 19, 2019 - New article focuses on integrative health, value-based medicine, and whole systems research
March 19, 2019 - Foamix Announces FDA Acceptance of New Drug Application for FMX101 Minocycline Foam for the Treatment of Moderate-to-Severe Acne
March 19, 2019 - National survey of emergency dept management of self-harm highlights successes, room for improvement
March 19, 2019 - Scientists reverse alcohol-seeking behavior in rats with flip of a switch
March 19, 2019 - Researchers hope blood test that accurately diagnoses fibromyalgia could be available within five years
March 19, 2019 - New Planmeca ProScanner 2.0 offers fast and dependable intraoral imaging
March 19, 2019 - A new option for reducing LDL cholesterol in patients at high risk for heart attack, stroke
March 19, 2019 - Common medications to treat heartburn linked to increased risks for kidney failure
March 19, 2019 - Current HBV genome sequences help deduce ancient human population movements into Australia
March 19, 2019 - Pure omega-3 prescription drug significantly reduces the occurrence of ischemic events
March 19, 2019 - Researchers use big data to gain better understanding of hepatitis E virus
March 19, 2019 - Use of synthetic psychedelic linked to improvements in depression and anxiety
March 19, 2019 - GARP protein can be a potential target for immunotherapy against colorectal cancer
March 19, 2019 - Knee Pain Not Tied to Activity Levels in Knee Osteoarthritis
March 19, 2019 - Study shows benefits of delayed cord clamping in healthy babies
March 19, 2019 - Pharmacists can undertake overall clinical responsibility for patients, shows study
March 19, 2019 - A cell’s “self-destruct” function could yield new therapies
March 19, 2019 - Latest advances and perspectives of all AI types used in pharmaceutical R&D
March 19, 2019 - Prophylactic cranial irradiation used as standard approach for patients with NSCLC
March 19, 2019 - Sugar-sweetened beverages may be linked with increased risk of cardiovascular mortality
March 19, 2019 - AHA News: Black Woman in Their 50s Face Especially High Stroke Risk
March 19, 2019 - Secrets of early life revealed from less than half a teaspoon of blood
March 19, 2019 - Immune cells engineered to tattle on suspicious cells in the body
March 19, 2019 - Heart attack patients who are taken to heart care centres directly survive longer
March 19, 2019 - IVF babies have increased in birthweight over the past 25 years, study reveals
March 19, 2019 - Study highlights the need for psychiatric care to be integrated into cancer treatment
March 19, 2019 - Testosterone treatment lowers recurrence rates in low-risk prostate cancer patients
March 19, 2019 - Caterpillars could hold the secret to new treatment for Osteoarthritis
March 19, 2019 - Parkinson’s treatment delivers a power-up to brain cell ‘batteries’
March 19, 2019 - Stanford launches new Institute for Human-Centered Artificial Intelligence
March 19, 2019 - Wireless earphones may cause cancer
March 18, 2019 - ACC/AHA guideline for prevention of cardiovascular disease released
March 18, 2019 - UTA nursing professor receives $6.575 million to attack musculoskeletal diseases
March 18, 2019 - Gene medication shows promise to treat spinal cord injuries
March 18, 2019 - First Human Study of “Robotic” RaniPill™ Capsule to Replace Injections Announced by Rani Therapeutics
March 18, 2019 - Food Allergy Testing: MedlinePlus Lab Test Information
March 18, 2019 - Altered brain activity patterns of Parkinson’s captured in mice
March 18, 2019 - Apple Heart Study demonstrates ability of wearable technology to detect atrial fibrillation | News Center
March 18, 2019 - Cardiovascular benefits of diabetes drug extend across a wide spectrum of patients, shows study
March 18, 2019 - Novel cardiac pump shows superior outcomes in patients with advanced heart failure
Harvard specialist focuses on opioid crisis as U.S. life expectancy drops

Harvard specialist focuses on opioid crisis as U.S. life expectancy drops

image_pdfDownload PDFimage_print
Harvard specialist focuses on opioid crisis as U.S. life expectancy drops
Credit: CDC.gov

Life expectancy in the U.S. declined in 2017, largely because of increases in suicide and lethal overdose, according to reports from the Centers for Disease Control and Prevention.

Though slight, the drop from 78.7 in 2016 to 78.6 in 2017 marks the third consecutive year of decline in a statistic that in 1900 stood at 49.24.

Experts see the fingerprint of the opioid epidemic in the numbers, as well as the economic inequality, depression, and despair that elevate suicide risk. R. Kathryn McHugh, an associate psychologist at McLean Hospital and an assistant professor of psychology at Harvard Medical School, responded to the CDC data in an interview with the Gazette.

Q&A with R. Kathryn McHugh

GAZETTE: One report showed that life expectancy fell between 2016 and 2017 and two others detailed the key factors in that decline: suicide and overdose deaths. Did those trends surprise you?

MCHUGH: Unfortunately, no. Both the suicide trend and drug overdose trend have been going on for many years now. Drug overdose in particular has been on an exponential growth curve since the late 1970s/early 1980s, with tremendous escalation since around 2013.

GAZETTE: The overdose statistics—up 9.6 percent—indicate a huge one-year increase. Does that reflect what you’re seeing in your clinical practice?

MCHUGH: Yes and no. The folks I see are all generally receiving frontline care, consisting of medications as well as behavioral therapies. However, we know that when someone leaves treatment their risk for relapse and overdose is very high.

The good news in this story is we actually have effective treatments that can both decrease opioid use and decrease overdose deaths. We actually know how to treat this disorder. It’s an issue of getting more people into treatment and retaining people in treatment.

GAZETTE: How do we do that better? I’ve heard other experts say the same thing about medication-assisted treatment: We know how to deal with this. But the number of overdose deaths is still going up. What are the main hurdles and how do we get over those?

MCHUGH: This is not a one-problem issue. We can’t just pull one lever and solve this crisis. It’s not just about opioid prescribing. It’s not just about pain. It’s not just about economic disparity. Really, there are a number of factors that come into play. This includes everything from access to health insurance and access to effective treatment, to physician prescribing practices and regulations on pain treatment, to issues of stigma, to the potency of the opioid supply.

Access to mental health care is another major issue. Psychiatric illnesses, exposure to trauma, and certainly suicidality are all part of the overdose crisis. We know psychiatric disorders are a risk for opioid medication misuse and for opioid-use disorder, as well as for suicide. However, access to effective mental health care remains extremely limited. So there are many levers that we need to pull.

GAZETTE: Do you see the overdose epidemic continuing?

MCHUGH: It’s hard to say. Unfortunately, last year’s increase of 9.6 percent suggests that the efforts that are now ongoing—and there’s quite a bit of attention on this—are not sufficient. A big part is access to fentanyl and fentanyl analogs, which are extremely potent opioids. That’s really driving this continued increase in deaths.

There are some pockets of good news. For example, the overdose rate has been dropping in some places, like in Massachusetts.

GAZETTE: Nationwide, fentanyl deaths were up 45 percent from 2016 to 2017. That made me wonder if fentanyl alone might be responsible for most of the increase.

MCHUGH: There are a couple of pieces to that. Heroin-related deaths have plateaued in the last few years. What the CDC report refers to as “natural and semisynthetic opioids”—which are mostly prescription opioids—are also starting to flatten out. The prescription opioids’ plateau is likely due to efforts to improve the safety of opioid prescribing. The overprescription of opioids was one of the driving factors in starting this crisis.

Really, the only thing increasing exponentially is fentanyl, and, since around 2013, that has really taken off. In the Boston area, the people I work with clinically will say to me that you can’t even get heroin anymore, everything on the street is fentanyl.

GAZETTE: Does that require a shift in approach?

MCHUGH: There are a couple of open questions about that. For overdose, Narcan does work with fentanyl, though you typically require higher doses and multiple administrations. In terms of the acute rescue, that ends up being an issue.

Certainly you can have more medical consequences because it’s a more severe overdose. The treatment of the disorder is the same—medication-assisted treatment, although there is more research needed on whether people who are using fentanyl have additional or different treatment needs. A big issue is if you have such potent opioids available and that’s what is accessible to people, the risk of unintentional overdose is heightened. We really worry about someone in treatment, doing well, who drops out. At that point, their tolerance for opioids has dropped and they are at very high risk of overdosing if they relapse.

GAZETTE: If they get an extra-potent drug like fentanyl …

MCHUGH: Exactly. And fentanyl doesn’t just show up in the heroin supply. People can buy from an illicit source something that looks like a standard prescription opioid—for example, it might look like a 30 mg Percocet—but it was produced illicitly and it has fentanyl in it. So, someone might think they know exactly what opioid dose they are getting, but they’re getting a much higher dose and are at a much higher risk of overdose. Fentanyl has also been showing up in illicitly produced benzodiazepines, which is another dangerous combination.

GAZETTE: How similar are this problem and suicide? I wonder if the underlying factors are related.

MCHUGH: We’ve drawn a false dichotomy between unintentional overdose and suicide. There’s evidence to suggest that you don’t fall in one category or another, that there are actually quite a few shades of gray between the two. For example, in what we might categorize as an unintentional overdose, there might be significant desire to die, or even ambivalence: “I don’t care if I live or die,” or “I know I might die but I just want some relief.”

There’s actually more overlap between these two behaviors than we typically acknowledge. Both suicide and overdose are exceptionally common in people with opioid-use disorder. Both contribute to the high mortality rates we see in this population.

The other piece is that many of the risk factors for overdose and suicide overlap. Risk factors at the individual level—exposure to trauma, chronic pain, psychiatric illness, financial or other kinds of stress—and even at the societal level—access to insurance, economic distress, access to opportunity, etc.—are common risks for both behaviors. There’s probably more overlap than we’re aware of at this point.

GAZETTE: Early on, you talked about what a complicated problem this is. But the increase in these numbers since 1999 is really just astonishing. The average reader might ask a simple question: What’s going on in this country?

MCHUGH: There’s a tendency to try to look for the smoking gun here. Is it the economy? Is it the [political] discourse? Is it hopelessness? There really are a number of different things that can be contributing.

Certainly, there’s data to suggest that economic depression is associated with both overdose and suicide. Some of the regions that have been hardest hit are regions in which opportunities have been limited, where there’s certainly economic stress. But opioid misuse is an issue that cuts across our entire society. There is no subgroup—men, women, any age, any socioeconomic group—that is immune from this problem.

You hear the term “deaths of despair” used to describe the epidemic of overdose and suicide. That certainly is a component of it, but there are also many other components that are really important to keep in mind. This is unquestionably a complex problem. We know that certain factors—exposure to trauma, untreated psychiatric illness, untreated pain—all play a role in risk for opioid misuse. And certainly access to prescriptions plays a role. The increase in opioid prescriptions over the last 20 to 30 years has been tremendous. Likewise with benzodiazepine prescriptions. These have been strongly correlated to the increases we see in overdose deaths.

GAZETTE: Your research involves finding or evaluating treatments. What are you learning from your work?

MCHUGH: There are a lot of really interesting things going on now, in terms of trying to address this in the research community. Part of what my work is focused on is, how do we address not just the substance-use disorder but all of the other things that come with it? For example, we are trying to answer questions about the role of stress in opioid misuse and how do we best treat the conditions that commonly co-occur with opioid-use disorder, such as pain and psychiatric illnesses.

We have a couple of studies ongoing now that examine how to best treat anxiety and stress in people with opioid-use disorder. If we address their opioid-use disorder but don’t help lift the depression or anxiety or post-traumatic stress disorder that comes along with it, even if people do successfully stop using opioids, they are still suffering quite a bit and are at a higher risk for relapse.

What we’re still learning is how to treat the whole person, treat all elements that come with this. In many cases it is also suicidal thoughts, it is also anxiety, it is also depression.

GAZETTE: And does that involve constructing a care team with different characteristics?

MCHUGH: Medication-assisted treatment is really the standard of care. It makes a tremendous difference in terms of getting people off opioids and keeping them from overdosing. Much of what we’re looking at now is how to improve the treatment-response rate.

Right now, the response to treatment is about 50 to 60 percent. Critically, that is many times better than no treatment, or medical detoxification alone. There is really no comparison in terms of outcomes. But we need to be doing better than that.

A lot of ongoing research is focusing on is how to build up the care team around people with behavioral treatments, such as cognitive behavioral therapy—which my work focuses on—as well as things like better case management, working with people to address things like social determinants of health, making sure that they have adequate health insurance and housing. There’s also increasing attention to the potential of peer-based services, whether that’s the self-help community or recovery coaches as part of the treatment team.

The data are still coming in. There really is a tremendous need for research in this area to continue to improve treatment, to improve models of care—like how to best link people from the hospital into medication-assisted treatment, and, critically, to begin to better understand effective prevention of opioid misuse so that we are catching people long before a bad outcome.


Naloxone rarely administered by layperson in opioid deaths


More information:
Sherry L Murphy et al. Mortality in the United States, 2017. NCHS Data Brief No. 328, November 2018, www.cdc.gov/nchs/products/databriefs/db328.htm


Provided by
Harvard University

This story is published courtesy of the Harvard Gazette, Harvard University’s official newspaper. For additional university news, visit Harvard.edu.

Citation:
Harvard specialist focuses on opioid crisis as U.S. life expectancy drops (2018, December 11)
retrieved 9 January 2019
from https://medicalxpress.com/news/2018-12-harvard-specialist-focuses-opioid-crisis.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.

Tagged with:

About author

Related Articles